Abstract
Epidermal growth factor receptor (EGFR) inhibition with erlotinib induces aquaporin-2 (AQP2) membrane accumulation with a phosphorylation pattern similar to vasopressin (VP). Here, we identify the ribosomal s6 kinase (RSK) as a major mediator phosphorylating AQP2 in this novel, erlotinib-induced pathway. In addition, we show that phosphoinositide-dependent kinase-1 (PDK1), a known activator of RSK, is implicated in this pathway: PDK1 inhibition blocks erlotinib-induced AQP2 S256 phosphorylation and membrane accumulation.
All Related Versions
Funding Information
  • American Society of Nephrology
  • HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK096586)
  • HHS | NIH | NIH Office of the Director (1S10OD021577-01)
  • HHS | NIH | NIH Office of the Director (1S10OD032211-01)
  • HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK057521)
  • HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK043351)

This publication has 75 references indexed in Scilit: